The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
US sweet protein startup Oobli has raised $18M and partnered with global ingredients giant Ingredion to develop ...
Novo Nordisk (NYSE: NVO) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...
Weight loss drugs continue to make headlines. A new study conducted by researchers from the University of Southern ...
A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...
A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
Ozempic and similar drugs are popular with consumers for their weight-loss properties, but a new study suggests they could ...
Doctors have begun noticing a trend: they all seem to get full before finishing dinner, and it's likely thanks to drugs like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results